ProCE Banner Activity

CE / CME

Current Controversies in HIV Management

Multimedia
Led by Joseph J. Eron, Jr., MD, a panel of experts discusses how they approach current controversies related to the management of patients with HIV infection.

Pharmacists : 1.50 contact {hours} ({0.15} CEUs)

Physicians : maximum of 1.50 AMA PRA Category 1 {Credits}

Released: May 01, 2017

Expiration: April 30, 2018

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joel E. Gallant

Joel E. Gallant, MD, MPH

Professor of Medicine & Epidemiology
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

W. David Hardy

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Kristen Marks

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Kathleen E. Squires

Kathleen E. Squires, MD

Professor of Medicine
Director, Division of Infectious Diseases
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie

Bristol Myers Squibb

Gilead

Janssen

Merck Human Health HIV

ViiV Healthcare

Target Audience

This activity is intended for HIV specialists, infectious diseases clinicians, hepatologists, gastroenterologists, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with HIV infection and/or chronic hepatitis C.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the results of recent clinical studies on ARTs, including new and emerging agents, in initial therapy and in switch strategies for HIV-infected patients
  • Effectively prevent or manage drug–drug interactions, adverse events, and other complications associated with HIV, ART, and comorbidities
  • Apply strategies to reduce the risk or impact of resistance to ART when managing HIV treatment

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen Virology, Merck, and ViiV and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Virology, and ViiV.

Joel E. Gallant, MD, MPH

Professor of Medicine & Epidemiology
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Sangamo, and ViiV.

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

Monica Gandhi, MD, MPH, has no real or apparent conflicts of interest to report.

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen Virology, Theratechnologies, and ViiV and funds for research support (to his institution) from Amgen, Bristol-Myers Squibb, CytoDyn, Gilead Sciences, Janssen Virology, Merck, and ViiV.

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Kristen M. Marks, MD, has disclosed that she has received funds for research support (paid to her institution) from Bristol-Myers Squibb, Gilead Sciences, and Merck.

Kathleen E. Squires, MD

Professor of Medicine
Director, Division of Infectious Diseases
Jefferson Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

Kathleen E. Squires, MD, has disclosed that she has served on advisory boards for scientific purposes for Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and ViiV and for marketing purposes for Gilead Sciences and Janssen and has received funds for research support (paid to Thomas Jefferson University) from Gilead Sciences.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program has been developed according to the ACPE Criteria for Quality and is assigned ACPE Universal Activity #0797-9999-17-038-H01-P. This program is designated for up to 1.5 contact hours (0.150 CEUs) of continuing pharmacy education credit.

Type of Activity Application

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 01, 2017, through April 30, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in HIV and HCV management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.